6 June 2017 at the City cardiological center in Almaty for the first time on the territory of CIS countries held a master class for the implantation of innovative bioresorbable frame Magmaris with a Professor, MD Werner Haberbosch (head of Department of internal diseases, Central hospital Fund rehabilitation Heidelberg (SRH), Munich, Germany) for the international exhibition EXPO-2017. Currently Magmaris is the world's first bioresorbable frame magnesium alloy.

The advantages of the bioresorbable scaffolds are:

  • Restoration of the natural contractility of the artery after complete resorption of the frame;
  • Minimizing local inflammation and restenosis due to the lack of foreign material in the lumen of the artery;
  • Simplification of the repeat intervention (PCI or CABG) or non-invasive investigations such as MRI, CT scan;
  • The lack of a psychological barrier for some patients – the absence of a permanent implant in the body.

Safety, better deliverability, and effective resorption proved by a number of clinical trials, such as BIOSOLVE-I and BIOSOLVE-II. Biennial the results of the study BIOSOLVE-II were reported in may 2017 at EuroPCR in Paris, France. After 24 months and after 12 months, there was no definite or probable thrombosis at the site of scaffold implantation.

During the master class on the introduction of new technologies in the Republic of Kazakhstan were implanted scaffolds Magmaris 5 patients with the participation of Professor MD Werner Haberbosch (head of Department of internal diseases, Central hospital Fund rehabilitation Heidelberg (SRH), Munich, Germany) and PhD of Orazbek of Israilovich Features (head of the Department of rethinkyoyo City cardiac center, President of the Kazakhstan society of interventional cardiologists and x-ray surgeons). In addition to practical part of Professor V. Habermas practical lecture about the experience of using the bioresorbable frame Magmaris.